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Background: Autoimmune disease-associated variants are preferentially found in regulatory regions in immune
cells, particularly CD4+ T cells. Linking such regulatory regions to gene promoters in disease-relevant cell contexts
facilitates identification of candidate disease genes.
Results: Within 4 h, activation of CD4+ T cells invokes changes in histone modifications and enhancer RNA
transcription that correspond to altered expression of the interacting genes identified by promoter capture Hi-C. By
integrating promoter capture Hi-C data with genetic associations for five autoimmune diseases, we prioritised
245 candidate genes with a median distance from peak signal to prioritised gene of 153 kb. Just under half
(108/245) prioritised genes related to activation-sensitive interactions. This included IL2RA, where allele-specific
expression analyses were consistent with its interaction-mediated regulation, illustrating the utility of the approach.
Conclusions: Our systematic experimental framework offers an alternative approach to candidate causal gene
identification for variants with cell state-specific functional effects, with achievable sample sizes.
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Genome-wide association studiesBackground
Genome-wide association studies (GWAS) in the last
decade have associated 324 distinct genomic regions to at
least one and often several autoimmune diseases (https://
www.immunobase.org). The majority of associated variants
lie outside genes [1] and presumably tag regulatory variants* Correspondence: cew54@cam.ac.uk
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from GWAS discovery to biological interpretation has
been hampered by lack of systematic methods to define
the gene(s) regulated by a given variant. The use of Hi-C
[4] and capture Hi-C to link GWAS identified variants to
their target genes for breast cancer [5] and autoimmune
diseases [6] using cell lines, has highlighted the potential
for mapping long-range interactions in advancing our
understanding of disease association. The observed cell
specificity of these interactions indicates a need to study
primary disease-relevant human cells and investigate the
extent to which cell state may affect inference.
Integration of GWAS signals with cell-specific chroma-
tin marks has highlighted the role of regulatory variation
in immune cells [7], and in particular CD4+ T cells, in
autoimmune diseases [8]. Concordantly, differences inle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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served in CD4+ T cells from autoimmune disease patients
compared to healthy controls [9, 10]. CD4+ T cells are at
the centre of the adaptive immune system and exquisite
control of activation is required to guide CD4+ T cell fate
through selection, expansion and differentiation into one
of a number of specialised subsets. Additionally, the
prominence of variants in physical proximity to genes as-
sociated with T cell regulation in autoimmune disease
GWAS and the association of human leukocyte antigen
haplotypes have suggested that control of T cell activation
is a key etiological pathway in development of many auto-
immune diseases [11].
We explored the effect of activation on CD4+ T cell
gene expression, chromatin states and chromosome
conformation. Promoter capture Hi-C (PCHi-C) was
used to map promoter interacting regions (PIRs) and to
relate activation-induced changes in gene expression to
changes in chromosome conformation and transcription of
(PCHi-C) linked enhancer RNAs (eRNAs). We also fine-
mapped the most probable causal variants for five auto-
immune diseases, autoimmune thyroid disease (ATD),
coeliac disease (CEL), rheumatoid arthritis (RA), systemic
lupus erythematosus (SLE) and type 1 diabetes (T1D). We
integrated these sources of information to derive a system-
atic prioritisation of candidate autoimmune disease genes.
Results
A time-course expression profile of early CD4+ T cell
activation
We profiled gene expression in CD4+ T cells from 20
healthy individuals across a 21 hour (h) activation time-
course and identified eight distinct gene modules by clus-
tering these profiles (Fig. 1, Additional file 1: Table S1).
This experimental approach focused on much earlier
events than previous large time-course studies (e.g. 6 h–
8 days [12]) and highlights the earliest changes that are ei-
ther not seen after or are returning towards baseline by
6 h (Additional file 2: Figure S1). Gene set enrichment
analysis using MSigDB Hallmark gene sets [13] demon-
strated that these modules captured temporally distinct
aspects of CD4+ T cell activation. For example, negative
regulators of TGF-beta signalling were rapidly upregulated
and returned to baseline by 4 h. Interferon responses, in-
flammatory responses and IL-2 and STAT5 signalling
pathways showed a more sustained upregulation be-
yond 6 h, while fatty acid metabolism was initially
downregulated in favour of oxidative phosphorylation.
PCHi-C captures dynamic enhancer-promoter interactions
We examined activated and non-activated CD4+ T cells
purified from healthy individuals in more detail at the 4-h
time point, at which the average fold change of genes re-
lated to cytokine signalling and inflammatory responsewas maximal, using total RNA sequencing (RNA-seq), his-
tone mark chromatin immunoprecipitation sequencing
(ChIP-seq), and PCHi-C. Of 8856 genes identified as
expressed (see ‘Methods’) in either condition (non-acti-
vated or activated), 25% were upregulated or downregu-
lated (1235 and 952 genes, respectively, false discovery
rate (FDR) < 0.01, Additional file 3: Table S2). We used
PCHi-C to characterise promoter interactions in activated
and non-activated CD4+ T cells. Our capture design baited
22,076 HindIII fragments (median length, 4 kb) which
contained the promoters of 29,131 annotated genes,
18,202 of which are protein-coding (Additional file 4:
Table S3). We detected 283,657 unique PCHi-C interac-
tions with the CHiCAGO pipeline [14], with 55% found in
both activation states and 22% and 23% found only in
non-activated and only in activated CD4+ T cells, respect-
ively (Additional file 5: Table S4). Of the baited promoter
fragments, 11,817 were involved in at least one inter-
action, with a median distance between interacting frag-
ments of 324 kb. Each interacting promoter fragment
connected to a median of eight PIRs, while each interact-
ing PIR was connected to a median of one promoter
fragment (Additional file 2: Figure S2).
We compared our interaction calls to an earlier ChIA-
PET dataset from non-activated CD4+ T cells [15] and
found we replicated over 50% of the longer-range inter-
actions (100 kb or greater), with replication rates over
tenfold greater for interactions found in non-activated
CD4+ T cells compared to interactions found only in
erythroblasts or megakaryocytes (Additional file 2:
Figure S3). We also compared histone modification
profiles in interacting fragments in CD4+ T cells to
interacting fragments found in erythroblasts or mega-
karyocytes. Both promoter fragments and, to a lesser
extent, PIRs were enriched for histone modifications asso-
ciated with transcriptionally active genes and regulatory el-
ements (H3K27ac, H3K4me1, H3K4me3; Additional file 2:
Figure S4) and changes in H3K27ac modifications at both
promoter fragments and PIRs correlated with changes in
gene expression upon activation. PIRs, but not promoter
fragments, showed overlap with regions previously anno-
tated as enhancers [16].
We found that absolute levels of gene expression cor-
related with the number of PIRs (Additional file 2:
Figure S5a; rho, 0.81), consistent with recent observa-
tions [15, 17]. We defined a subset of PCHi-C interac-
tions that were specifically gained or lost upon
activation (2334 and 1866, respectively, FDR < 0.01) and
found that the direction of change (gain or loss) at these
differential interactions agreed with the direction of dif-
ferential expression (upregulated or downregulated) at the
module level (Fig. 2). We further found that dynamic
changes in gene expression upon activation correlated
with changing numbers of PIRs. Notably, the pattern was
ab
Fig. 1 a Summary of genomic profiling of CD4+ T cells during activation with anti-CD3/CD28 beads. We examined gene expression using microarray
in activated and non-activated CD4+ T cells across 21 h and assayed cells in more detail at the 4-h time point using ChIP-seq, RNA-seq and PCHi-C. n
gives the number of individuals† or pools* assayed. b Eight modules of co-regulated genes were identified and eigengenes are plotted
for each individual (solid lines = activated, dashed lines = non-activated), with heavy lines showing the average eigengene across individuals.
We characterised these modules by gene set enrichment analysis within the MSigDB HALLMARK gene sets; where significant gene sets
were found, up to three shown per module. n is the number of genes in each module
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approximately twofold the change associated with a lost
interaction (Fig. 3a). Given the > 6-h median half-life of
messenger RNAs (mRNAs) expressed in T cells [18]
(Additional file 2: Figure S5b), it is possible that the
relatively smaller changes associated with lost interac-
tions are due to the persistence of downregulated tran-
scripts at the early stages of T cell activation.
As we sequenced total RNA without a poly(A) selection
step, we were able to detect regulatory region RNAs
(regRNAs), which are generally non-polyadenylated and
serve as a mark for promoter and enhancer activity [19].
We defined 6147 ‘expressed’ regRNAs (see ‘Methods’) that
mapped within regulatory regions defined by a 15 stateChromHMM [20] model (Additional file 2: Figure S6) and
validated them by comparison to an existing cap analysis
of gene expression (CAGE) dataset [21] which has been
successfully used to catalogue active enhancers [22]. We
found 2888/3897 (74%) regRNAs expressed in non-
activated cells overlap CAGE defined enhancers. This sug-
gests that the combination of chromatin state annotation
and total RNA-seq data presents an alternative approach
to capture active enhancers.
Almost half (48%) of expressed regRNAs showed dif-
ferential expression after activation (2254/681 upregu-
lated/downregulated; FDR < 0.01). To determine whether
activity at these regRNAs could be related to that at
PCHi-C linked genes, we focused attention on a subset
Fig. 2 Change in PCHi-C interactions correlate with change in gene expression. a Distribution of significant (FDR < 0.01) fold changes induced by
activation of CD4+ T cells in (top) gene expression and (bottom) differential PCHi-C interactions for differentially expressed genes in by module.
b Median significant expression and interaction fold changes by module are correlated (Spearman rank correlation)
Burren et al. Genome Biology  (2017) 18:165 Page 4 of 19of 640 intergenic regRNAs, which correspond to a defin-
ition of eRNAs [23]. Of these, 404 (63%) overlapped
PIRs detected in CD4+ T cells and we found significant
agreement in the direction of fold changes at eRNAs
and their PCHi-C linked protein-coding genes in activated
CD4+ T cells (p < 0.0001, Fig. 3b). We also observed a syn-
ergy between regRNA expression and the estimated effect
of a PIR on expression with a gain or loss of a PIR overlap-
ping a differentially regulated regRNA having the largest
estimated effect on gene expression (Fig. 3c), supporting a
sequential model of gene activation [24]. While regRNA
function is still unknown [23], our results demonstrate the
detection, by PCHi-C, of condition-specific connectivity
between promoters and enhancers involved coordinating
gene regulation.
PCHi-C-facilitated mapping of candidate disease-causal
genes
We defined an experimental framework to integrate
PCHi-C interactions with GWAS data to map candi-
date disease-causal genes for autoimmune diseases
(Fig. 4). First, to confirm that PCHi-C interactions
inform interpretation of autoimmune disease GWAS,
we tested whether PIRs were enriched for auto-
immune disease GWAS signals by testing for differ-
ent distributions of GWAS p values in PIRs of
activated or non-activated CD4+ T cells compared to
non-lymphoid cells (megakaryocytes and erythro-
blasts) and then in PIRs of activated compared to
non-activated CD4+ T cells. To perform the test, we
used blockshifter [17] which accounts for correlation
between (1) neighbouring variants in the GWAS dataand (2) neighbouring HindIII fragments in the inter-
acting data by rotating one dataset with respect to
the other, as previously proposed [25]. This method
appropriately controls type 1 error rates, in contrast
to methods based on counting associated SNP/PIRs
which ignore correlation, such as a Fisher’s exact test
(Additional file 2: Figure S7). We found autoimmune
GWAS signals were enriched in CD4+ T cell PIRs com-
pared to non-autoimmune GWAS signals (Wilcoxon p =
2.5 × 10−7) and preferentially so in activated vs. non-
activated cells (Wilcoxon p = 4.8 × 10−5; Fig. 4).
Next, we fine-mapped causal variants for five auto-
immune diseases using genetic data from a dense targeted
genotype array, the ImmunoChip (ATD, CEL, RA, T1D)
and summary data from GWAS data imputed to 1000 Ge-
nomes Project (RA, SLE; Additional file 6: Table S5). For
the ImmunoChip datasets, with full genotype data, we also
imputed to 1000 Genomes and used a Bayesian fine-
mapping approach [26], which avoids the need for step-
wise regression or assumptions of single causal variants
and which provides a measure of posterior belief that any
given variant is causal by aggregating posterior support
over models containing that variant. Variant-level results
are given in Additional files 7 and 8: Tables S6a and S6b,
and show that of 73 regions with genetic association sig-
nals to at least one disease (minimum p < 5 × 10−8; 106
disease associations), nine regions have strong evidence
that they contain more than one causal variant (posterior
probability > 0.5), among them the well-studied region on
chromosome 10 containing the candidate gene IL2RA
[26]. For the GWAS summary data, we make the simplify-
ing assumption that there exists a single causal variant in
ac
b
Fig. 3 PCHi-C interactions and enhancer activity predict change in gene expression. a Change in gene expression at protein coding genes
(log2 fold change, y-axis) correlates with the number of PIRs gained or lost upon activation (x-axis). b Fold change at transcribed sequence
within the intergenic subset of regulatory regions (‘eRNAs’) was more likely to agree with the direction of protein-coding gene fold change
when the two are linked by PCHi-C (red) in activated CD4+ T cells compared to pairs of eRNA and protein-coding genes formed without regard to
PCHi-C derived interactions (background, grey, p < 10−4). Interactions were categorised as control (present only in megakaryocytes and erythroblasts,
our control cells), invariant (‘invar’; present in non-activated and activated CD4+ T cells), ‘loss’ (present in non-activated but not activated CD4+ T cells
and significantly downregulated at FDR < 0.01) or ‘gain’ (present in activated but not non-activated CD4+ T cells and significantly upregulated
at FDR < 0.01). c Gain or loss of PIRs upon activation predicts change in gene expression, with the estimated effect more pronounced if accompanied
by upregulation or downregulation at an eRNA. Points show estimated effect on gene expression of each interaction and lines the 95% confidence
interval. PIRs categorised as in (b). eRNAs categorised as no (undetected), invariant (‘invar’, detected in non-activated and activated CD4+ T
cells, differential expression FDR ≥ 0.01), up (upregulated; FDR < 0.01) or down (downregulated; FDR < 0.01). Bar plot (top) shows the number
of interactions underlying each estimate. Note that eRNA = down, PIR = gain (light gray) has only one observation so no confidence interval
can be formed and is shown for completeness only
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posterior probabilities that each variant is causal [27].
To integrate these variant level data with PCHi-C
interactions and prioritise protein-coding genes as
candidate causal genes for each autoimmune disease,
for each gene, we aggregated posterior support over all
models containing variants in PIRs for the gene promoter,
within the promoter fragment or within its immediate
neighbour fragments. Neighbouring fragments are in-
cluded because of limitations in the ability of PCHi-C to
detect very proximal interactions (within a regionconsisting of the promoter baited fragment and one Hin-
dIII fragment either side). The majority of gene scores
were close to 0 (99% of genes have a score < 0.05) and we
chose to use a threshold of 0.5 to call genes prioritised for
further investigation. Having both ImmunoChip and sum-
mary GWAS data for RA allowed us to compare the two
methods. Overlap was encouraging: of 24 genes priori-
tised for RA from ImmunoChip, 20 had a gene score >
0.5 in the GWAS prioritisation, and a further three had
gene scores > 0.2. The remaining gene, MDN1, corre-
sponded to a region which has a stronger association
a b
c
Fig. 4 An experimental framework for identifying disease-causal genes. a Before prioritising genes, enrichment of GWAS signals in PCHi-C interacting
regions should be tested to confirm the tissue and context are relevant to disease. Then, probabilistic fine-mapping of causal variants from the GWAS
data can be integrated with the interaction data to prioritise candidate disease-causal genes, a list which can be iteratively filtered using genomic
datasets to focus on (differentially) expressed genes and variants which overlap regions of open or active chromatin. b Autoimmune disease
GWAS signals are enriched in PIRs in CD4+ T cells generally compared to control cells (blockshifter Z score, x-axis) and in PIRs in activated
compared to non-activated CD4+ T cells (blockshifter Z score, y-axis). Text labels correspond to datasets described in Additional file 6: Table S5. c Genes
were prioritised with a COGS score > 0.5 across five autoimmune diseases using genome-wide (GWAS) or targeted genotyping array (ImmunoChip)
data. The numbers at each node give the number of genes prioritised at that level. Where there is evidence to split into one of two non-overlapping
hypotheses (log10 ratio of gene scores > 3), the genes cascade down the tree. Act and NonAct correspond to gene scores derived using PCHi-C data
only in activated or non-activated cells, respectively. Where the evidence does not confidently predict which of the two possibilities is
more likely, genes are ‘stuck’ at the parent node (number given in brackets). When the same gene was prioritised for multiple diseases,
we assigned fractional counts to each node, defined as the proportion of the n diseases for which the gene was prioritised at that node.
Because of duplicate results between GWAS and ImmunoChip datasets, the total number of prioritised genes is 252 (see Table 1)
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which may reflect the greater power of direct genotyping
vs. imputation, given that the RA-ImmunoChip signal is
echoed in ATD and T1D (Additional file 2: Figure S8). We
prioritised a total of 245 unique protein-coding genes, 108
of which related to activation sensitive interactions
(Additional files 9 and 10: Tables S7a and 7b, Fig. 4). Of
118 prioritised genes which could be related through in-
teractions to a known susceptibility region, 63 (48%) lay
outside that disease susceptibility region. The median dis-
tance from peak signal to prioritised gene was 153 kb.
Note that prioritisation can be one (variant)-to-many
(genes) because a single PIR can interact with more than
one promoter and promoter fragments can contain more
than one gene promoter. Note also that the score reflectsboth PCHi-C interactions and the strength and shape of
association signals (Additional file 2: Figure S9), therefore
a subset of prioritised genes relate to an aggregation over
sub-genomewide significant GWAS signals. This is there-
fore a ‘long’ list of prioritised genes which requires further
filtering (Table 1). A total of 179 (of 245) prioritised genes
were expressed in at least one activation state; we
highlight specifically the subset of 118 expressed
genes which can be related to a genome-wide signifi-
cant GWAS signal through proximity of a genome-
wide significant SNP (p < 5 × 10−8) to a PIR. Of these, 82
were differentially expressed, 48 related to activation-
sensitive interactions and 63 showed overlap of GWAS
fine-mapped variants with an expressed eRNA (Additional
file 9: Table S7a).
Table 1 Number of genes prioritised for autoimmune disease
susceptibility under successive filters
Group Description Number of genes
1 Total 245
2 … Expressed 179
3 … … Proximal GWAS significant SNP
(p < 5 × 10−8)
118
4 … … … Prioritised gene differentially
expressed upon activation
82
5 … … … Prioritisation relates to activation
sensitive interactions
48
6 … … … GWAS signal overlaps expressed
regRNA in at least one state
63
Note that group 2 is a subset of group 1, group 3 is a subset of group 2, and
groups 4, 5 and 6 are all subsets of group 3 but not necessarily of each other
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underlying gene regulation and the context-driven
effects that common autoimmune disease-associated
variants may have on candidate genes. Our findings
are consistent with, and extend, previous observations
[7, 8] and we highlight six examples which exemplify
both activation-specific and activation-invariant
interactions.Fig. 5 TROVE2 and UCLH5 on chromosome 1 are prioritised for CEL. The ru
top tracks show PIRs for prioritised genes in non-activated (n) and activated
PIRs containing credible SNPs from our fine-mapping. The total number of
each gene in each activation state. Dark grey boxes indicate promoter fragm
and red boxes, PIRs overlapping fine-mapped disease-associated variants. Th
and vertical red lines. Gene positions and orientation (Ensembl v75) are sho
strands. H3K27ac background-adjusted read count is shown in non-activate
show regions considered through ChromHMM to have regulatory marksExemplar regions
Here we highlight specific examples of prioritised genes
with plausible autoimmune disease candidacy which illus-
trate three characteristics we found frequently, namely: (1)
the identification of candidate genes some distance from
association signals; (2) the tendency for multiple gene pro-
moters to be identified as interacting with the same sets of
disease-associated variants; and (3) genes prioritised in
only one state of activation.
As an example of the first, CEL has been associated
with a region on chromosome 1q31.2, for which RGS1
has been named as a causal candidate due to proximity
of associated variants to its promoter [28]. Sub-genome-
wide significant signals for T1D (min. p = 1.5 × 10−6)
across the same SNPs which are associated with CEL
have been interpreted as a co-localising T1D signal in
the region [29]. RGS1 has recently been shown to have a
role in the function of T follicular helper cells in mice
[30], the frequencies of which and their associated IL-21
production have been shown to be increased in T1D
patients [31]. However, our analysis also prioritises, in
activated T cells, the strong functional candidate genes
TROVE2 and UCHL5, over half a megabase distant and
with three intervening genes not prioritised (Fig. 5).ler shows chromosome location, with HindIII sites marked by ticks. The
(a) CD4+ T cells. Green and purple lines are used to highlight those
interacting fragments per PCHi-C bait is indicated in parentheses for
ents; light grey boxes, PIRs containing no disease associated variants;
e position of the fine-mapped variant area is indicated by red boxes
wn above log2 read counts for RNA-seq forward (red) and reverse (blue)
d (green line) and activated (purple line) and boxes on the regRNA track
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a deubiquitinating enzyme that stabilises several Smad
proteins and TGFBR1, key components of the TGF-beta1
signalling pathway [32, 33]. TROVE2 is significantly up-
regulated upon activation (FDR = 0.005) and encodes
Ro60, an RNA binding protein that indirectly regulates
type-I IFN-responses by controlling endogenous Alu RNA
levels [34]. A global anti-inflammatory effect for TROVE2
expression would fit with its effects on gut (CEL) and
pancreatic islets (T1D).
A similar situation is seen in the chromosome 1q32.1
region associated with T1D in which IL10 has been
named as a causal candidate gene [35]. Together with
IL10, prioritised through proximity of credible SNPs to
the IL10 promoter, we prioritised other IL10 gene family
members IL19, IL20 and IL24 as well as two members of
a conserved three-gene immunoglobulin-receptor cluster
(FCMR and PIGR, Additional file 2: Figure S10). While
IL19, IL20 and PIGR were not expressed in CD4+ T cells,
FCMR was downregulated and IL24 and IL10 were
upregulated following CD4+ T cell activation. IL-10 is
recognised as an important anti-inflammatory cytokine
in health and disease [36] and candidate genes FCMR
and IL24 are components of a recently identified pro-
inflammatory module in Th17 cells [37].
This region also exemplifies characteristic 2: a ten-
dency for multiple gene promoters to be identified as
interacting with the same sets of disease-associated vari-
ants. Parallel results have demonstrated co-regulation of
multiple PCHi-C interacting genes by a single variant [37],
suggesting that disease-related variants may act on mul-
tiple genes simultaneously, consistent with the finding that
regulatory elements can interact with multiple promoters
[38–40]. In this region, clusters of multiple adjacent PIRs
were be detected for the same promoter fragments. It re-
mains to be further validated whether all PIRs detected
within such clusters correspond to ‘causal’ interactions or
whether some such PIRs are ‘bystanders’ of strong inter-
action signals occurring in their vicinity. The use of PCHi-
C nonetheless adds considerable resolution compared to
simply considering topologically associating domains
(TADs), which have a median length of 415 kb in naive
CD4+ T cells [17] compared to a median of 37.5 kb total
PIR length per gene in non-activated CD4+ T cells (Add-
itional file 2: Figure S11).
Multiple neighbouring genes were also prioritised on
chromosome 16q24.1: EMC8, COX4I1 and IRF8, the last
only in activated T cells, for two diseases: RA and SLE
(Additional file 2: Figure S12). Candidate causal variants
for SLE and RA fine-mapped to distinct PIRs, yet all
these PIRs interact with the same gene promoters, sug-
gesting that interactions, possibly specific to different
CD4+ T cell subsets, may allow us to unite discordant
GWAS signals for related diseases [6, 41, 42]. EMC8 andCOX4I1 RNA expression was relatively unchanged by
activation, whereas IRF8 expression was upregulated
97-fold, coincident with the induction of 16 intergenic
IRF8 PIRs, four of which overlap autoimmune disease
fine-mapped variants. Although the dominant effect
of IRF8 is to control the maturation and function of the
mononuclear phagocytic system [43], a T cell-intrinsic
function regulating CD4+ Th17 differentiation has been
proposed [44]. Our data further link the control of Th17
responses to susceptibility to autoimmune disease includ-
ing RA and SLE [45].
Another notable example, AHR, was one of the 38 genes
we prioritised in only one state of activation (characteristic
3, Fig. 4): for RA, AHR was prioritised specifically in acti-
vated T cells rather than non-activated T cells (Additional
file 2: Figure S13). AHR is a high affinity receptor for
toxins in cigarette smoke that has been linked to RA pre-
viously through differential expression in synovial fluid of
patients, though not through GWAS [46]. Our analysis
prioritises AHR for RA due to a sub-genome-wide signifi-
cant signal (rs71540792, p = 2.9 × 10−7) and invites at-
tempts to validate the genetic association in additional RA
patients.
Interaction-mediated regulation of IL2RA expression
Given our prior interest in the potential for autoimmune-
disease associated genetic variants to regulate IL2RA
expression [42], we were interested to note PCHi-C interac-
tions between some of these variants and the IL2RA
promoter. We attempted to confirm the predicted func-
tional effects on IL2RA expression experimentally. IL2RA
encodes CD25, a component of the key trimeric cytokine
receptor that is essential for high-affinity binding of IL-2,
regulatory T cell survival and T effector cell differentiation
and function [47]. Multiple variants in and near IL2RA have
been associated with a number of autoimmune diseases
[35, 48–50]. We have previously fine-mapped genetic
causal variants for T1D and multiple sclerosis (MS) in the
IL2RA region [26], identifying five groups of SNPs in intron
1 and upstream of IL2RA, each of which is likely to contain
a single disease-causal variant. Out of the group of eight
SNPs previously denoted ‘A’ [26], three (rs12722508,
rs7909519 and rs61839660) are located in an area of active
chromatin in intron 1, within a PIR that interacts with the
IL2RA promoter in both activated and non-activated CD4+
T cells (Fig. 6a). These three SNPs are also in LD with
rs12722495 (r2 > 0.86) that has previously been associated
with differential surface expression of CD25 on memory T
cells [42] and differential responses to IL-2 in activated
Tregs and memory T cells [51]. We measured the relative
expression of IL2RA mRNA in five individuals heterozy-
gous across all group A SNPs and homozygous across most
other associated SNP groups, in a 4-h activation time-
course of CD4+ T cells. Allelic imbalance was observed
ab c
Fig. 6 PCHi-C interactions link the IL2RA promoter to autoimmune disease-associated genetic variation, which leads to expression differences in IL2RA
mRNA. a The ruler shows chromosome location, with HindIII sites marked by ticks. The top tracks show PIRs for prioritised genes in non-activated (n)
and activated (a) CD4+ T cells. Green and purple lines are used to highlight those PIRs containing credible SNPs for the autoimmune diseases T1D and
MS fine mapped on chromosome 10p15. Six groups of SNPs (A–F) highlighted in Wallace et al. [26] are shown, although note that group B was found
unlikely to be causal. The total number of interacting fragments per PCHi-C bait is indicated in parentheses for each gene in each activation state. Dark
grey boxes indicate promoter fragments; light grey boxes, PIRs containing no disease-associated variants; and coloured boxes, PIRs overlapping
fine-mapped disease-associated variants. PCHi-C interactions link a region overlapping group A in non-activated and activated CD4+ T cells to
the IL2RA promoter (dark grey box) and regions overlapping groups D and F in activated CD4+ T cells only. RNA-seq reads (log2 scale, red = forward
strand, blue= reverse strand) highlight the upregulation of IL2RA expression upon activation and concomitant increases in H3K27ac (non-activated, n,
green line; activated, a, purple line) in the regions linked to the IL2RA promoter. Red vertical lines mark the positions of the group A SNPs. Numbers in
parentheses show the total number of IL2RA PIRs detected in each state. Here we show those PIRs proximal to the IL2RA promoter. Comprehensive
interaction data can be viewed at https://www.chicp.org. b Allelic imbalance in mRNA expression in total CD4+ T cells from individuals
heterozygous for group A SNPs using rs12722495 as a reporter SNP in non-activated (non) and activated (act) CD4+ T cells cultured for 2
or 4 h, compared to genomic DNA (gDNA, expected ratio = 1). Allelic ratio is defined as the ratio of counts of T to C alleles. ‘x’ = geometric mean of
the allelic ratio over 2–3 replicates within each of 4–5 individuals; p values from a Wilcoxon rank sum test comparing complementary DNA (cDNA) to
gDNA are shown. ‘+’ shows the geometric mean allelic ratio over all individuals. c Allelic imbalance in mRNA expression in memory CD4+ T cells differs
between ex vivo (time 0) and 4-h activated samples from eight individuals heterozygous for group A SNPs using rs12722495 as a reporter SNP. p value
from a paired Wilcoxon signed rank test is shown
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UTR in non-activated CD4+ T cells in each individual
(Fig. 6b; Additional file 2: Figure S14a), validating a func-
tional effect of the PCHi-C-derived interaction between thisPIR and the IL2RA promoter in non-activated CD4+ Tcells.
While the allelic imbalance was maintained in non-
activated cells cultured for 2–4 h, the imbalance was lost in
cells activated under our in vitro conditions. Since
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A SNPs has previously been observed on memory
CD4+ T cells but not the naive or Treg subsets that
are also present in the total CD4+ T cell population
[42], we purified memory cells from eight group A hetero-
zygous individuals and confirmed activation-induced loss
of allelic imbalance of IL2RA mRNA expression in this
more homogeneous population (Fig. 6c, Additional file 2:
Figure S14b; Wilcoxon p = 0.007). IL2RA is one of the most
strongly upregulated genes upon CD4+ T cell activation,
showing a 65-fold change in expression in our RNA-seq
data. Concordant with the genome-wide pattern (Fig. 3),
the IL2RA promoter fragment gains PIRs that accumulate
H3K27ac modifications upon activation and these, as well
as potentially other changes marked by an increase in
H3K27ac modification at rs61839660 and across the group
A SNPs in intron 1, could account for the loss of allelic im-
balance. These results emphasise the importance of steady-
state CD25 levels on CD4+ T cells for the disease associ-
ation mediated by the group A SNPs, levels which will
make the different subsets of CD4+ Tcells more or less sen-
sitive to the differentiation and activation events caused by
IL-2 exposure in vivo [52].
Discussion
Our results illustrate the changes in chromosome con-
formation detected by PCHi-C in a single cell type in re-
sponse to a single activation condition. That the PCHi-C
technique can indeed link enhancers to their target genes
is supported by our evidence that the direction of fold
changes at eRNAs is connected to those at their PCHi-C
linked protein-coding genes. Our results also provide sup-
port for the candidacy of certain genes and sequences in
GWAS regions as causal for disease. Recent attempts to
link GWAS signals to variation in gene expression in pri-
mary human cells have sometimes found only limited
overlap [53–55]. One explanation may be that these ex-
periments miss effects in specific cell subsets or states, es-
pecially given the transcriptional diversity between the
many subsets of memory CD4+ T cells [56]. We highlight
the complex nature of disease association at the IL2RA re-
gion where additional PIRs for IL2RA gained upon activa-
tion overlap other fine-mapped disease-causal variants
(Fig. 6a), suggesting that other allelically imbalanced states
may exist in activated cells, which may also correspond to
altered disease risk. For example, the PIR containing
rs61839660, a group A SNP, also contains an activation
expression quantitative trait locus (eQTL) for IL2RA ex-
pression in CD4+ T effectors [57] marked by rs12251836,
which is unlinked to the group A variants and was not as-
sociated with T1D [57]. Furthermore, rs61839660 itself
has recently been reported as a QTL for methylation of
the IL2RA promoter as well as an eQTL for IL2RA expres-
sion in whole blood [55, 58]. The differences betweenCD25 expression in different T cell subsets [59, 60] and
the rapid activation-induced changes in gene and regula-
tory expression, chromatin marks and chromosome inter-
actions we observe, imply that a large diversity of cell
types and states will need to be assayed to fully under-
stand the identity and effects of autoimmune disease-
causal variants.
Our approach, like others such as eQTL analyses and
integration of GWAS variants with chromatin state infor-
mation, offers a view of disease through the prism of puri-
fied cell subsets in specific states of activation. However, a
more complete range of cell types and activation states
will be needed for the comprehensive understanding of
complex diseases for which multiple cell types are
aetiologically involved. It will be challenging to assay this
greater diversity of cell types and states in the large num-
bers of individuals needed for traditional eQTL studies,
particularly for cell-type or condition-specific eQTLs that
have been shown to generally have weaker effects [61, 62].
Allele-specific expression (ASE) is a more powerful design
to quantify the effects of genetic variation on gene expres-
sion with modest sample sizes [63] and the targeted ASE
approach that we adopt enables testing of individual
variants or haplotypes at which donors are selected to
be heterozygous, while controlling for other poten-
tially related variants at which donors are selected to
be homozygous.
Conclusions
Here we have presented an approach for connecting
disease-associated variants derived from GWAS with
putative target genes based on promoter interactome
maps obtained with PCHi-C. By using statistical fine-
mapping of GWAS data, integrated with PCHi-C, to high-
light both likely disease-causal variants and their potential
target genes, we enable the design of targeted ASE ana-
lyses for functional confirmation of individual effects. This
systematic experimental framework offers an alternative
approach to candidate causal gene identification for vari-
ants with cell state-specific functional effects, with achiev-
able sample sizes.
Methods
CD4+ T cell purification and activation, preparation for
genomics assays
Blood samples were obtained from healthy donors se-
lected from the Cambridge BioResource. Donors were ex-
cluded if they were diagnosed with autoimmune disease
or cancer, were receiving immunosuppressants, cytotoxic
agents or intravenous immunoglobulin or had been
vaccinated or received antibiotics in the 2–4 weeks
preceding the blood donation. CD4+ T cells were iso-
lated from whole blood using RosetteSep (STEMCELL
technologies, Canada) according to the manufacturer’s
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pure; range, 92.9–98.7%) were washed in X-VIVO 15
supplemented with 1% AB serum (Lonza, Switzerland)
and penicillin/streptomycin (Invitrogen, UK) and plated in
96-well CELLSTAR U-bottomed plates (Greiner Bio-One,
Austria) at a concentration of 2.5 × 105 cells/well. Cells
were left untreated or stimulated with Dynabeads human
T activator CD3/CD28 beads (Invitrogen, UK) at a ratio of
1 bead : 3 cells for 4 h at 37 °C and 5% CO2. Cells were
harvested, centrifuged, supernatant removed and either:
(1) resuspended in RLT buffer (RNeasy micro kit, Qiagen,
Germany) for RNA-seq (0.75-1 × 106 CD4+ T cells/pool
and activation state); or (2) fixed in formaldehyde for cap-
ture Hi-C (44–101 × 106 CD4+ T cells/pool and activation
state) or ChIP-seq (16–26 × 106 CD4+ T cells/pool and
activation state) as detailed in [17].
ChIP-seq (H3K27ac, H3K4me1, H3K4me3, H3K27me3,
H3K9me3, H3K36me3) was carried out according to
BLUEPRINT protocols [17]. Formaldehyde fixed cells
were lysed, sheared and DNA sonicated using a Bioruptor
Pico (Diagenode). Sonicated DNA was pre-cleared
(Dynabeads Protein A, Thermo Fisher) and ChIP per-
formed using BLUEPRINT validated antibodies and the
IP-Star automated platform (Diagenode). Libraries were
prepared and indexed using the iDeal library prepar-
ation kit (Diagenode) and sequenced (Illumina HiSeq,
paired-end).
For PCHi-C [17], DNA was digested overnight
with HindIII, end-labelled with biotin-14-dATP and
ligated in preserved nuclei. De-crosslinked DNA was
sheared to an average size of 400 bp, end-repaired and
adenine-tailed. Following size selection (250–550 bp frag-
ments), biotinylated ligation fragments were immobilised,
ligated to paired-end adaptors and libraries amplified (7–8
polymerase chain reaction [PCR] amplification rounds).
Biotinylated 120-mer RNA baits targeting both ends of
HindIII restriction fragments that overlap Ensembl-
annotated promoters within the Ensembl categories of
protein-coding, non-coding, antisense, snRNA, miRNA and
snoRNA were used to capture targets [64]. After en-
richment, the library was further amplified (four PCR
cycles) and sequenced on the Illumina HiSeq 2500
platform. Each PCHi-C library was sequenced over
three lanes generating 50-bp paired-end reads.PCHi-C interaction calls
Raw sequencing reads were processed using the HiCUP
pipeline [65] and interaction confidence scores were com-
puted using the CHiCAGO pipeline [14] as previously
described [17]. We considered the set of interactions with
high confidence scores (>5) in this paper.
Raw PCHi-C read counts from three replicates and two
conditions were transformed into a matrix and a trimmedmean of M-values normalisation was applied to account
for library size differences. Subsequently, a voom normal-
isation was applied to log-transformed counts in order to
estimate precision weights per contact and differential
interaction estimates were obtained after fitting a linear
model on a paired design, using the limma Bioconductor
R package [66].Microarray measurement of gene expression
We recruited 20 healthy volunteers from the Cambridge
BioResource. Total CD4+ T cells were isolated from
whole blood within 2 h of venepuncture by RosetteSep
(StemCell Technologies). To assess the transcriptional
variation in response to TCR stimulation, 106 CD4+ T
cells were cultured in U-bottom 96-well plates in the
presence or absence of human T activator CD3/CD28
beads at a ratio of 1 bead : 3 cells. Cells were harvested
at 2, 4, 6 or 21 h post stimulation or after 0, 6 or 21 h in
the absence of stimulation. Three samples from the 6-h
unstimulated time point were omitted from the study
due to insufficient cell numbers and a further four sam-
ples were dropped after quality control, resulting in a
total of 133 samples that were included in the final ana-
lysis. RNA was isolated using the RNAeasy kit (Qiagen)
according to the manufacturer’s instructions.
cDNA libraries were synthesised from 200 ng total
RNA using a whole-transcript expression kit (Ambion)
according to the manufacturer’s instructions and hybri-
dised to Human Gene 1.1 ST arrays (Affymetrix). Micro-
array data were normalised using a variance stabilising
transformation [67] and differential expression was ana-
lysed in a paired design using limma [66]. Genes were
clustered into modules using WGCNA [68].ChIP-sequencing and regulatory annotation
ChIP-seq reads for all histone modification assays and
control experiments were mapped to the reference gen-
ome using BWA-MEM [69], a Burrows-Wheeler genome
aligner. Samtools [70] was employed to filter secondary
and low-quality alignments (we retained all read pair
alignments with PHRED score > 40 that matched all bits
in SAM octal flag 3 and did not match any bits in SAM
octal flag 3840). The remaining alignments were sorted,
indexed and a whole-genome pileup was produced for
each histone modification, sample and condition triple.
We used ChromHMM [20], a multivariate hidden
Markov model, to perform a whole-genome segmenta-
tion of chromatin states for each activation condition.
First, we binarised read pileups for each chromatin mark
pileup using the corresponding control experiment as a
background model. Second, we estimated the parameters
of a 15-state hidden Markov model (a larger state model
resulted in redundant states) using chromosome 1 data
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times using different random seeds to assess conver-
gence. Third, a whole-genome segmentation was pro-
duced for each condition by running the obtained model
on the remaining chromosomes. Each state from the
obtained model was manually annotated and states indi-
cating the presence of promoter or enhancer chromatin
tags were selected (E4–E11, Additional file 2: Figure S6).
Overlapping promoter or enhancer regions in non-
activated and activated genome segmentations were
merged to create a CD4+ T cell regulatory annotation.
Thus, we defined 53,534 regulatory regions (Additional
files 11, 12 and 13: Tables S8a–S8c).
RNA sequencing
Total RNA was isolated using the RNeasy kit (Qiagen)
and the concentrations and integrity were quantified using
Bioanalyzer (Agilent); all samples reached RINs > 9.8. Two
pools of RNA were generated from three and four donors
and for each experimental condition. cDNA libraries were
prepared from 1 ug total RNA using the stranded NEB-
Next Ultra Directional RNA kit (New England Biolabs)
and sequenced on HiSeq (Illumina) at an average coverage
of 38 million paired-end reads/pool. RNA-seq reads were
trimmed to remove traces of library adapters by matching
each read with a library of contaminants using Cutadapt
[71], a semi-global alignment algorithm. Owing to our
interest in detecting functional enhancers, which consti-
tute transcription units on their own right, we mapped
reads to the human genome using STAR [72], a splicing-
aware aligner. This frees us from relying on a transcrip-
tome annotation which would require exact boundaries
and strand information for all features of interest, some-
thing not available in case of promoters and enhancers.
After alignment, we employed Samtools [70] to discard
reads with an unmapped pair, secondary alignments and
low-quality alignments. The resulting read dataset, with
an average of 33 million paired-end reads/sample, was
sorted and indexed. We used FastQC (v0.11.3, http://
www.bioinformatics.babraham.ac.uk/projects/fastqc/) to
ensure all samples had regular GC content (sum of devi-
ations from normal includes less than 15% of reads),
base content per position (difference A vs. T and G vs. C
less than 10% at all positions) and kmer counts (no im-
balance of kmers with p < 0.01) as defined by the tool.
We augmented Ensembl 75 gene annotations with regu-
latory region definitions obtained from our ChIP-seq
analysis described above and defined them as present in
both genome strands due to their bi-directional tran-
scription potential. For each RNA-seq sample, we quan-
tified expression of genomic and regulatory features in a
two-step strand-aware process using HTSeq. [73] For
each gene we counted the number of reads that fell
exactly within its exonic regions and did not map toother genomic elements. For each regulatory feature, we
counted the number of reads that fell exactly within its
defined boundaries and did not map to other genomic
or regulatory elements.
By construction, this quantification scheme counts
each read at most once towards at most one feature.
Furthermore, strand information is essential to be able
to assign reads to features in regions with overlapping
annotations. For example, distinguishing intronic eRNAs
from pre-mRNA requires reads originating from regula-
tory activity in the opposite strand from the gene.
Feature counts were transformed into a matrix and a
trimmed mean of M-values normalisation was applied to
account for library size differences, plus a filter to dis-
card features below an expression threshold of < 0.4
counts per million mapped reads in at least two samples,
a rather low cutoff, to allow for regulatory RNAs to
enter differential expression calculations. This threshold
equates to approximately 15 reads, given our mapped
library sizes of ~35 million paired-end reads. A voom
normalisation was applied to log-transformed counts in
order to estimate precision weights per gene and differ-
ential expression estimates were obtained after fitting a
linear model on a paired design, using the limma Bio-
conductor R package [66]. There was a strong correl-
ation (rho = 0.81) between microarray and RNA-seq fold
change estimates at 4 h.Comparison of regRNAs to FANTOM CAGE data
We compared expressed regRNA regions detected in our
non-activated CD4+ T cell samples vs. those found using
CAGE-seq by the FANTOM5 Consortium. RNA-seq, using
a regulatory reference obtained from chromatin states,
yields 17,175 features expressed with at least 0.4 counts per
million in both non-activated CD4+ T cell samples. Among
those, 3897 correspond to regulatory regions. Unstimulated
CD4+ samples from FANTOM5 (http://fantom.gsc.ri-
ken.jp/5/datafiles/latest/basic/human.primary_cell.hCAGE/,
samples 10,853, 11,955 and 11998) contain 266,710 loci
expressed (with at least one read) in all three samples.
We found 13,178 of our 17,175 expressed CD4+ T cell
features overlap expressed loci in CAGE data (77%). Con-
versely, 243,596/266,710 CAGE loci overlap CD4+ T cell
features (91%). Similarly, 2888/3897 expressed regRNAs
overlap expressed loci in CAGE data (74%).Comparison of PCHi-C and ChIA-PET interactions
We downloaded supplementary Table 1 from http://
www.nature.com/cr/journal/v22/n3/extref/cr201215x1.xlsx
[15] and counted the overlaps of PCHi-C interactions
from CD4+ T cells and comparitor cells (megakaryoctyes
and erythroblasts) in distance bins. R code to replicate the
analysis is at https://github.com/chr1swallace/cd4-pchic/
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teractions requires correction for the expected higher
density of random collisions at shorter distances [74]
which are explicitly modelled by CHICAGO [14] used
in this study but not in the ChIA-PET study [15]. As
a result, we expected a higher false-positive rate from
the ChIA-PET data at shorter distances.
Regression of gene expression against PIR count and
eRNA expression
We related measures of gene expression (absolute log2
counts or log2 fold change) to numbers of PIRs or numbers
of PIRs overlapping specific features using linear re-
gression. We used logistic regression to relate agree-
ment between fold change direction at PCHi-C linked
protein-coding genes and eRNAs. We used robust clus-
tered variance estimates to account for the shared baits
for some interactions across genes with the same prey.
Enrichment of chromatin marks in interacting baits
and prey were assessed by logistic regression modelling
of a binary outcome variable (fragment overlapped spe-
cific chromatin peak) against a fragment width and a
categorical explanatory variable (whether the HindIII
fragment was a bait or prey and the cell state the inter-
action was identified in), using block bootstrapping of
baited fragments (https://github.com/chr1swallace/geno-
mic.autocorr) to account for spatial correlation between
neighbouring fragments.
GWAS summary statistics
We used a compendium of 31 GWAS datasets [17]
(Additional file 6: Table S5). Briefly, we downloaded
publicly available GWAS statistics for 31 traits. Where
necessary we used the liftOver utility to convert these to
GRCh37 coordinates. To remove spurious association
signals, we removed variants with p < 5 × 10−8 for which
there were no variants in LD (r2 > 0.6 using 1000
genomes EUR cohort as a reference genotype panel) or
within 50 kb with p < 10−5. We masked the MHC region
(GRCh37:chr6:25-35 Mb) from all downstream analysis
due to its extended LD and known strong and complex
associations with autoimmune diseases.
Comparison of GWAS data and PIRs requires dense
genotyping coverage. For GWAS which did not include
summary statistics imputed for non-genotyped SNPs, we
used a poor man’s imputation (PMI) method [17] to
impute. We imputed p values at ungenotyped variants from
1000 Genomes EUR phase 3 by replacing missing values
with those of their nearest proxy variant with r2 > 0.6, if one
existed. Variants that were included in the study but
did not map to the reference genotype set were also
discarded.
To calculate posterior probabilities that each SNP is
causal under a single causal variant assumption, we dividedthe genome into linkage disequilibrium blocks of 1 cM
based on data from the HapMap project (ftp://
ftp.ncbi.nlm.nih.gov/hapmap/recombination/2011-01_pha-
seII_B37/). For each region excluding the MHC we used
code modified from Giambartolomei et al. [75] to compute
approximate Bayes factors for each variant using the
Wakefield approximation [76]; thus, posterior probabil-
ities that each variant was causal as previously proposed
[77]. The method assumes a normal prior on the popu-
lation log relative risk centred at 0 and we set the vari-
ance of this distribution to 0.04, equivalent to a 95%
belief that the true relative risk is in the range of 0.66–
1.5 at any causal variant. We set the prior probability
that any variant is causal for disease to 10−4.
Testing of the enrichment of GWAS summary statistics in
PIRs using blockshifter
We used the blockshifter method [17] (https://github.com/
ollyburren/CHIGP) to test for a difference between variant
posterior probability distributions in HindIII fragments
with interactions identified in test and control cell types
using the mean posterior probability as a measure of cen-
tral location. Blockshifter controls for correlation within
the GWAS data due to LD and interaction restriction
fragment block structure by employing a rotating label
technique similar to that described in GoShifter [25] to
generate an empirical distribution of the difference in
means under the null hypothesis of equal means in the
test and control set. Runs of one or more PIRs (separated
by at most one HindIII fragment) are combined into
‘blocks’, that are labelled unmixed (either test or control
PIRs) or mixed (block contains both test and control
PIRs). Unmixed blocks are permuted in a standard fashion
by reassigning either test or control labels randomly,
taking into account the number of blocks in the observed
sets. Mixed blocks are permuted by conceptually circular-
ising each block and rotating the labels. A key parameter
is the gap size—the number of non-interacting HindIII
fragments allowed within a single block, with larger gaps
allowing for more extended correlation.
We used simulation to characterise the type 1 error
and power of blockshifter under different conditions and
to select an optimal gap size. First, from the Javierre
et al. dataset [17], we selected a test (Activated or Non
Activated CD4+ T Cells) and control (Megakaryocyte or
Erythroblast) set of PIRs with a CHiCAGO score > 5, as
a reference set for blockshifter input.
Using the European 1000 genomes reference panel,
we simulated GWAS summary statistics, under differ-
ent scenarios of GWAS/PIR enrichment. We split
chromosome 1 into 1 cM LD blocks and used refer-
ence genotypes to compute a covariance matrix for
variants with minor allele frequency above 1%, Σ.
GWAS Z scores can be simulated as multivariate
Burren et al. Genome Biology  (2017) 18:165 Page 14 of 19normal with mean μ and variance Σ [78]. Each block
may contain no causal variants (GWASnull, μ = 0) or
one (GWASalt). For GWASalt blocks, we pick a single
causal variant, i, and calculate the expected non-
centrality parameter (NCP) for a 1 degree of freedom
chi-square test of association at this variant and its
neighbours. This framework is natural because, under a
single causal variant assumption, the NCP at any vari-
ant j can be expressed as the NCP at the causal variant
multiplied by the r2 between variants i and j [79]. In each
case, we set the NCP at the causal variant to 80 to ensure
that each causal variant was genome-wide significant (p <
5 × 10−8). μ is defined as the square root of this con-
structed NCP vector.
For all scenarios, we randomly chose 50 GWASalt
blocks leaving the remaining 219 GWASnull. Enrich-
ment is determined by the preferential location of
simulated causal variants within test PIRs. In all sce-
narios, each causal variant has a 50% chance of lying
within a PIR, to mirror a real GWAS in which we ex-
pect only a proportion of causal variants to be regula-
tory in any given cell type. Under the enrichment-null
scenario, used to confirm control of type 1 error rate,
the remaining variants were assigned to PIRs without
regard for whether they were identified in test or
control tissues. To examine power, we considered two
different scenarios with PIR-localised causal variants
chosen to be located specifically in test PIRs with ei-
ther 50% probability, scenario power (1) or 100%, sce-
nario power (2). Note that a PIR from the test set
may also be in the control set, thus, as with a real
GWAS, not all causal variants will be informative for
this test of enrichment.
For each scenario, we further considered variable
levels of genotyping density, corresponding to full geno-
typing (everything in 1000 Genomes), HapMap imput-
ation (the subset of SNPs also in Stahl et al. [80] dataset)
or genotyping array (the subset of SNPs also on the Illu-
mina 550 k array). Where genotyping density is less than
full, we used our proposed PMI strategy to fill in Z
scores for missing SNPs.
We ran blockshifter, with 1000 null permutations, for
each scenario and PMI condition for 4000 simulated
GWAS, with a blockshifter superblock gap size parameter
(the number of contiguous non-PIR HindIII fragments
allowed within one superblock) of between 1 and 20 and
supplying numbers of cases and controls from the RA
dataset [49].
For comparison, we also investigated the behaviour of
a naive test for enrichment for the null scenario. We
computed a 2 × 2 table variants according to test and
control PIR overlap, and whether a variant’s posterior
probability of causality exceeded an arbitrary threshold
of 0.01, and Fisher’s exact test to test for enrichment.Enrichment of GWAS summary statistics in CD4+ and
activated CD4+ PIRs
We compared the following sets using all GWAS
summary statistics, with a superblock gap size of 5 (ob-
tained from simulations above) and 10,000 permutations
under the null:
 Total CD4+ Activated + Total CD4+ NonActivated
(test) vs. endothelial precursors + megakaryocytes
(control)
 Total CD4+ Activated (test) vs. Total
CD4+ NonActivated (control)Variant posterior probabilities of inclusion, full genotype
data (ImmunoChip)
We carried out formal imputation to 1000 Genomes
Project EUR data using IMPUTE2 [81] and fine-mapped
causal variants in each of the 179 regions where a mini-
mum p < 0.0001 was observed using a stochastic search
method which allows for multiple causal variants in a re-
gion (https://github.com/chr1swallace/GUESSFM) [26].
Despite the pre-selection of regions associating with
autoimmune diseases on the ImmunoChip, we chose to
again set the prior probability that any variant was causal
to 10−4, to align our analysis with that applied to the
GWAS summary data. The prior probability for individ-
ual models follows a binomial distribution, according to
the number of causal variants represented, so that the
prior for each of the (nk) k- SNP causal variant models
was (10−4)k(1–10−4)(n-k) where n is the number of SNPs
considered in the region. The posterior probabilities for
models that contained variants which overlapped PIRs
for each gene were aggregated to compute PIR-level
marginal posterior probabilities of inclusion.Variant posterior probabilities of inclusion, summary
statistics
Where we have only summary statistics of GWAS data
already imputed to 1000 Genomes, we divided the gen-
ome into linkage disequilibrium blocks of 0.1 cM based
on data from the HapMap project (ftp://ftp.ncbi.nlm.nih.-
gov/hapmap/recombination/2011-01_phaseII_B37/). For
each region, excluding the MHC, we use code modified
from Giambartolomei et al. [75] to compute approximate
Bayes factors for each variant using the Wakefield ap-
proximation [76]; thus, posterior probabilities that each
variant was causal assuming at most one causal variant
per region as previously proposed [77].Computation of gene prioritisation scores
We used the COGS method [17] (https://github.com/olly-
burren/CHIGP) to prioritise genes for further analysis.
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categories it overlaps for each annotated gene, if any:
1. coding variant: the variant overlaps the location of a
coding variant for the target gene;
2. promoter variant: the variant lies in a region baited
for the target gene or adjacent restriction fragment;
3. PIR variant: the variant lies in a region overlapping
any PIR interacting with the target gene.
We produced combined gene/category scores by aggre-
gating, within LD blocks, over models with a variant in a
given set of PIRs (interacting regions) or over HindIII frag-
ments baited for the gene promoter and immediate neigh-
bours (promoter regions) or over coding variants to
generate marginal probabilities of inclusion (MPPI) for
each hypothesised group. We combine these probabilities
across LD blocks, i, using standard rules of probability to
approximate the posterior probability that at least one LD
block contains a causal variant:
gene score ¼ 1 −
Y
i ∈ LD blocks
1 − score for i½ ð Þ
Thus, the score takes a value between 0 and 1, with
1 indicating the strongest support. We report all re-
sults with score > 0.01 in Additional file 9: Table S7b,
but focus in this manuscript on the subset with
scores > 0.5.
Because COGS aggregates over multiple signals, a gene
may be prioritised because of many weak signals or few
strong signals in interacting regions. To estimate the
expected number of prioritised genes for a typical GWAS
signal, we considered the subset of 76 input regions with
genome-wide significant signals (p < 5 × 10−8) in Immuno-
Chip datasets. We prioritised at least one gene with a
COGS score > 0.5 in 35 regions, with a median of three
genes/region (interquartile range [IQR] = 1.5-4). Equiva-
lent analysis of the genome-wide significant GWAS sig-
nals prioritised a median of two genes/region (IQR = 1–3).
This suggests that this algorithm might be expected
to prioritise at least one gene in about half the
genome-wide significant regions input when run on a
relevant cell type.
We developed a hierarchical heuristic method to as-
certain for each target gene, which was the mostly likely
component and cell state. First, for each gene we com-
pute the gene score due to genic variants (components
1 + 2) and variants in PIRs (component 3) using all avail-
able tissue interactions for that gene. While components
1 and 2 are fixed for a given gene and trait, the contribu-
tion of variants overlapping PIRs varies depending on
the tissue context being examined. We use the ratio of
the genic score to PIRs score in a similar manner to aBayes factor to decide whether causal variants contribut-
ing to the gene score are more likely to lie within the
gene or within its associated PIRs. If a genic location is
more likely (gene.score ratio > 3) we iterate and compare
if the gene score due to coding variants (component 1)
is more likely than for promoter variants (component 2).
Similarly, if PIRs are more likely, we compare PIR gene
scores for activated vs. non-activated cells. If at any stage
no branch is substantially preferred over its competitor
(ratio of gene scores < 3), we return the previous set as
most likely, otherwise we continue until a single cell
state/set is chosen. In this way, we can prioritise genes
based on the overall score and label as to a likely mech-
anism for candidate causal variants.
Allele-specific expression assays
Total CD4+ T cells were isolated from five healthy donors
and activated as described above and were harvested after
0, 2 and 4 h in RLT Plus buffer. Selected donors were het-
erozygous for all eight group A SNPs and homozygous for
group C and F SNPs. Two and three of the donors were
homozygous for the group D and E SNP groups, respect-
ively (Additional file 14: Table S9). Memory CD4+ T cells
were sorted from cryopreserved PBMC from an additional
eight healthy donors as viable, αβ TCR+, CD4+, CD45RA−,
CD127+ and CD27+ cells using a FACSAria III cell sorter
(BD Biosciences). Sorted cells were either activated for 4 h
in culture as described above or resuspended directly in
RLT plus buffer post-sort. Total RNA was extracted using
Qiagen RNeasy Micro plus kit and cDNA was synthesised
using Superscript III reverse transcriptase (Thermo
Fisher) according to the manufacturer’s instructions. To
perform allele-expression experiments we used a modified
version of a previously described method for quantify-
ing methylation in bisulphite sequence data [82]. A
two-stage PCR was used, the first round primers were
designed to flank the variant of interest using Primer3
(http://bioinfo.ut.ee/primer3-0.4.0/primer3/) and adaptor
sequences were added to the primers (Sigma), shown as
lowercase letters (rs61839660_ASE_F tgtaaaacgacggccagt
GCACACACCTATCCTAGCCT, rs61839660_ASE_R cag
gaaacagctatgaccCCCACAGAATCACCCACTCT, product
size 114 bp; rs12244380_ASE_F tgtaaaacgacggccagtTTCG
TGGGAGTTGAGAGTGG, rs12244380_ASE_R caggaaac
agctatgaccTTAAAAGAGTTCGCTGGGCC, product size
180 bp; rs12722495_ASE_F tgtaaaacgacggccagtGTGAGT
TTCAATCCTAAGTGCGA, rs12722495_ASE_R cagga
aacagctatgaccATTAAGCGGACTCTCTGGGG, product size
97 bp). The first-round PCR contains 10 μL of Qiagen
multiplex PCR mastermix, 0.5 μL of 10 nmol forward
primer, 0.5 μL of 10 nmol reverse primer, 4 μL of
cDNA and made up to 20 μL with ultra-pure water.
The PCR cycling conditions were 95 °C for 15 min hot
start, followed by 30 cycles of the following steps: 95 °C
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a 72 °C for 10-min cycle. The first-round PCR product
was cleaned using AmpureXP beads (Beckman Coulter)
according to manufacturer’s instructions. To add Illumina
sequence compatible ends to the individual first-round
PCR amplicons, additional primers were designed to in-
corporate P1 and A sequences plus sample-specific index
sequences in the A primer, through hybridisation to
adapter sequence present on the first-round gene-specific
primers. Index sequences are as published [82]. The
second-round PCR contained 8 μL of Qiagen multiplex
PCR mastermix, 2.0 μL of ultra-pure water, 0.35 μL of
each forward and reverse index primer and 5.3 μL of
Ampure XP-cleaned first-round PCR product. The PCR
cycling conditions were 95 °C for 15 min hot start,
followed by seven cycles of the following steps: 95 °C
for 30 s, 56 °C for 90 s, 72 °C for 60 s, finishing with
72 °C for a 10-min cycle. All PCR products were
pooled at equimolar concentrations based on quantifi-
cation on the Shimadzu Multina. AmpureXP beads
were used to remove unincorporated primers from
the product pool. We used the Kapa Bioscience library
quantification kit to accurately quantify the library accord-
ing to the manufacturer’s instructions before sequencing
on an Illumina MiSeq v3 reagents (2 × 300 bp reads).
Statistical analysis of allele-specific expression data
Sequence data were processed using the Methpup package
(https://github.com/ollyburren/Methpup) to extract counts
of each allele at rs12722495 and rs12244380 (Additional
file 15: Table S10). Individuals were part of a larger cohort
genotyped on the ImmunoChip and were phased using
snphap (https://github.com/chr1swallace/snphap) to con-
firm which allele at each SNP was carried on the same
chromosome as A2 = rs12722495:C or A1 = rs12722495:T.
Allelic imbalance was quantified as the ratio A2/A1 and
was averaged across replicates within individuals using a
geometric mean. Allelic ratios in cDNA and gDNA were
compared using Wilcoxon rank sum tests. p values are
shown in Fig. 6b and Additional file 2: Figure S14. Full
details are in https://github.com/chr1swallace/cd4-pchic/
blob/master/ASE/IL2RA-ASE.R.
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distributions of interacting fragments. Figure S3. Validation of PCHi-C by
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Additional file 8: Table S6b. Results of GWAS summary statistic
fine-mapping. (GZ 2833 kb)
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whether the input data was GWAS or ImmunoChip (ICHIP) and
whether summary statistic (SS) or GUESSFM (GF) fine-mapping was
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or, if expressed, whether there was differential expression at the FDR
< 0.01 level (up, down or nsig). Similarly, ‘diff.erna’ indicates whether
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75 genomic features plus CD4-specific regulatory regions inferred from
chromatin states. These regulatory regions have been named with identifiers
containing a CD4R prefix, assigned a regulatory biotype and marked as
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potential. (GZ 39807 kb)
Additional file 12: Table S8b. Whole-genome segmentation of
non-activated and activated CD4 T cells into 15 states obtained from
a CHROMHMM analysis using ChIP-seq data for activated CD4+ T cells.
(GZ 1551 kb)
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